Currently, there are 70.94M common shares owned by the public and among those 38.46M shares have been available to trade.
The company’s stock has a 5-day price change of -2.99% and -7.61% over the past three months. KNSA shares are trading 3.76% year to date (YTD), with the 12-month market performance up to 16.97% higher. It has a 12-month low price of $13.56 and touched a high of $22.09 over the same period. KNSA has an average intraday trading volume of 338.63K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.74%, -3.11%, and 0.58% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares accounts for 51.51% of the company’s 70.94M shares outstanding.
It has a market capitalization of $1.29B and a beta (3y monthly) value of 0.37. The stock’s trailing 12-month PE ratio is 168.05, while the earnings-per-share (ttm) stands at $0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.96% over the week and 2.91% over the month.
Earnings per share for the fiscal year are expected to decrease by -157.23%, and 615.48% over the next financial year.
Looking at the support for the KNSA, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on May 03, 2024, with the firm’s price target at $34. BofA Securities coverage for the Kiniksa Pharmaceuticals Ltd (KNSA) stock in a research note released on June 29, 2020 offered a Buy rating with a price target of $40. BofA/Merrill was of a view on April 01, 2020 that the stock is Buy, while Barclays gave the stock Overweight rating on March 11, 2019, issuing a price target of $26. Wedbush on their part issued Outperform rating on December 12, 2018.
